The European Medicines Agency (EMA) and the European Centre for the Prevention and Control of Medicinal Products (ECDC) issued, in a joint statement on Tuesday 6 September, recommendations for the use of vaccines adapted to new variants of concern in this autumn and winter’s Covid-19 vaccination campaigns.
The first two bivalent vaccines have recently been licenced in the EU: a vaccine developed by Pfizer-BioNTech and a vaccine developed by Moderna adapted to the original SARS-CoV-2 and...